Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD iPSC-derived cardiomyocyte spheroids for systolic heart failure
jRCT2033250454Phase 2Recruiting
- Sponsor
- Heartseed Inc.
- Start
- Jan 2026
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of HS-001 in heart failure with reduced ejection fraction (HFrEF), coronary arteriosclerosis and dilated cardiomyopathy (DCM) (2 cohorts), sponsored by Heartseed Inc. Primary endpoint: Safety. Started Jan 2026; status: recruiting.
02
Drugs
HS-001
03
Conditions
heart failure with reduced ejection fraction (HFrEF)coronary arteriosclerosisdilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on jRCT2033250454.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2033250454.